SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma

Summary

RATIONALE: SU5416 may stop the growth of multiple myeloma by stopping blood flow to the cancer cells. PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have refractory or relapsed multiple myeloma.

Timeline

Start

2000-06

Primary completion

2003-01

Completion

2003-01

Drugs

Indications